甲磺酸阿帕替尼治疗晚期非小细胞肺癌的研究现状

Research status of apatinib for advanced non-small cell lung cancer

甲磺酸阿帕替尼,一种小分子酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI),作用于血管内皮生长因子受体-2(vascular endothelial growth factor receptor-2,VEGFR-2),强效抑制内皮细胞新生血管生成。阿帕替尼是在中国获得批准的第一代口服抗血管生成药物,用于晚期胃癌标准化疗失败的后续治疗。目前阿帕替尼单药或者联合其他治疗在晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)中的临床研究正在积极开展,多数均显示一定生存获益。本文详细介绍近年阿帕替尼在晚期NSCLC中的研究现状,为后期临床应用提供参考。

Apatinib is a novel small-molecule tyrosine kinase inhibitor(TKI),targeting vascular endothelial growth factor receptor-2(VEGFR-2).It could strongly inhibit the neovascularization of endothelial cells.Apatinib is a first-generation oral anti-angiogenesis drug approved in the People's Republic of China for use as a subsequent line of treatment for advanced gastric cancer.At present,the clinical studies of apatinib monotherapy,or combined with other treatment in advanced non-small cell lung cancer(NSCLC)are being actively carried out.The most of clinical studies have shown effective survival benefits.This article reviewed the current research of apatinib in advanced NSCLC in recent years to provide reference for further using of apatinib in clinic.